Xcout Intel
Leucid Bio competitors & alternatives
The 12 closest competitors and alternatives to Leucid Bio among life sciences companies — ranked by similarity to what Leucid Bio actually does, not by market-cap band.
Subscribe to see Leucid Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Leucid Bio
Leucid Bio is a privately held clinical-stage biotechnology company headquartered in London, United Kingdom, with research operations based at Guy's Hospital. The firm translates CAR-T cell research originating from King's College London into novel cancer immunotherapies.
Leucid Bio at a glance
Leucid Bio is a life sciences company headquartered in United Kingdom, founded in 2014. Its most recent funding round, Series A, raised $16M in October 2021. Xcout tracks 10 named people at Leucid Bio, including Filippo Petti (Chief Executive Officer).
Leucid Bio leadership
- Filippo PettiChief Executive Officer
- Mark DochertyCFO & COO
- Ian MiscampbellChairman
- Dr John MaherCSO
- Belinda CarlsenVP Clin Ops
- Marc DaviesVP R&D
4 more named people on record for Leucid Bio, with roles, board committees and tenure — see the full roster →
Leucid Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $16M | 6 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Leucid Bio competitors
Ranked by semantic similarity — how close each company is to Leucid Bio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Biotechnology
Centauri Therapeutics Limited is a privately held immunotherapy company with its primary headquarters located in London, United Kingdom.
Biotechnology
Grey Wolf Therapeutics is a biotechnology company headquartered in the UK focused on delivering a new class of treatments to improve the lives of people with cancers and autoimmune disorders.
Biotechnology
Alchemab Therapeutics Ltd is a biotechnology company headquartered in London, England, focused on pioneering patient-centric antibody discovery and development.
Biotechnology
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Similar life sciences company
Cytospire Therapeutics Limited is a biotechnology research company based in London, United Kingdom. The company is focused on developing a portfolio of next-generation immune cell engagers to improve patients' lives.
Biotechnology
Laverock Therapeutics is a biotechnology research company headquartered in London, England, that develops programmable advanced therapies.
Biotechnology
AviadoBio is a biotechnology research company formed on pioneering research from King's College London and the UK Dementia Research Institute. Headquartered in London, the company focuses on therapeutic advancements.
Biotechnology
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Biotechnology
Myricx Bio is a UK biotech company headquartered in London. It specializes in the discovery and development of a novel class of selective cytotoxic payloads for Antibody-Drug Conjugates (ADCs).
Biotechnology
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Biotech
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel T cell receptor engineered T cell therapies to fight cancer. The company is involved in biotechnology research and has a presence in Berlin, Germany.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Leucid Bio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Leucid Bioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →